Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orteronel plus Prednisone in mCRPC Post-Docetaxel (ELM-PC 5)
NCT01193257Phase 3Completed
- Sponsor
- Millennium Pharmaceuticals
- Start
- Nov 2010
- Primary completion
- May 2013
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial in metastatic castration-resistant prostate cancer (mCRPC) comparing Orteronel + Prednisone with Placebo + Prednisone (2 arms). Primary endpoint: Overall Survival up to 4.5 years. Started Nov 2010; status: completed.
02
Drugs
orteronel
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT01193257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01193257.